60
603658.SHG Autobio Diagnostics Co Ltd
- Market cap
- CNY 22.3B
- P/E
- 21.3x
- P/B
- 2.48x
- ROE
- 12.5%
- Dividend yield
- 3.25%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603658.SHG undervalued?
Graham number603658.SHG trades 53.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Autobio Diagnostics Co Ltd fundamental analysis
No fundamental analysis for Autobio Diagnostics Co Ltd yet.
Autobio Diagnostics Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Autobio Diagnostics Co Ltd
Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. The company offers immunoassay, biochemistry, and microbiology products; reagents and instruments; and technical and support, and training services, as well as engages in biology research and development activities. Its immunoassay products consist of AutoLumo S900 and AutoLumo A1860 that provides user e…
Full company profileAutobio Diagnostics Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Autobio Diagnostics Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 980M | 1.40B | 1.93B | 2.68B | 2.98B | 3.77B | 4.44B | 4.44B | 4.47B | 4.23B | 4.32B |
| Gross Profit | 706M | 945M | 1.27B | 1.77B | 1.76B | 2.22B | 2.60B | 2.83B | 2.89B | 2.77B | 2.96B |
| Operating Income | 394M | 506M | 654M | 894M | 856M | 1.08B | 1.30B | 1.37B | 1.25B | 1.15B | 1.24B |
| EBITDA | 462M | 602M | 795M | 1.08B | 1.08B | 1.34B | 1.54B | 1.64B | 1.62B | 1.70B | 1.25B |
| Net Income | 350M | 447M | 563M | 774M | 748M | 974M | 1.17B | 1.22B | 1.19B | 1.07B | 1.13B |
| EPS | 0.68 | 0.82 | 1.03 | 1.42 | 1.34 | 1.66 | 2.00 | 2.10 | 2.07 | 1.87 | 1.98 |
| Balance Sheet | |||||||||||
| Total Assets | 1.82B | 2.19B | 2.66B | 4.26B | 8.14B | 9.23B | 10.5B | 11.6B | 11.9B | 12.3B | 12.3B |
| Total Liabilities | 177M | 498M | 691M | 1.62B | 1.55B | 1.83B | 2.56B | 2.89B | 3.18B | 3.27B | 3.21B |
| Shareholders' Equity | 1.64B | 1.67B | 1.93B | 2.56B | 6.48B | 7.28B | 7.78B | 8.54B | 8.62B | 8.93B | 9.02B |
| Cash & Short-term Investments | 56.2M | 26.9M | 58.5M | 257M | 413M | 777M | 1.14B | 4.52B | 4.04B | 592M | 602M |
| Total Debt | - | 39.0M | 96.9M | 795M | 200M | 236M | 133M | 368M | 253M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 416M | 482M | 654M | 843M | 995M | 1.46B | 1.56B | 1.47B | 1.31B | 1.34B | - |
| Capital Expenditure | 237M | 455M | 410M | 762M | 1.12B | 1.07B | 938M | 900M | 664M | 604M | 473M |
| Free Cash Flow | 178M | 26.6M | 244M | 80.8M | -121M | 395M | 620M | 569M | 645M | 737M | 238M |
| Ratios | |||||||||||
| ROE | 21.3% | 26.8% | 29.2% | 30.3% | 11.5% | 13.4% | 15.0% | 14.3% | 13.9% | 12.0% | 12.5% |
| ROA | 19.2% | 20.4% | 21.2% | 18.2% | 9.2% | 10.5% | 11.1% | 10.5% | 10.1% | 8.7% | 9.2% |
| Net Profit Margin | 35.7% | 31.9% | 29.2% | 28.9% | 25.1% | 25.9% | 26.3% | 27.4% | 26.7% | 25.3% | 26.1% |
| Debt to Equity | - | 0.02x | 0.05x | 0.31x | 0.03x | 0.03x | 0.02x | 0.04x | 0.03x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Autobio Diagnostics Co Ltd dividends
- Dividend yield
- 3.25%
- Forward dividend
- 1.31 CNY
- Payout ratio
- 68.0%
- Ex-dividend date
- Jun 1, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 727M | 1.27 | 68.0% |
| 2024 | CNY 623M | 1.08 | 52.2% |
| 2023 | CNY 479M | 0.83 | 39.4% |
| 2022 | CNY 419M | 0.72 | 35.9% |
| 2021 | CNY 383M | 0.65 | 39.4% |
| 2020 | CNY 388M | 0.69 | 51.8% |
| 2019 | CNY 336M | 0.62 | 43.4% |
| 2018 | CNY 306M | 0.56 | 54.4% |
| 2017 | CNY 425M | 0.78 | 95.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on May 27, 2021.
Who owns Autobio Diagnostics Co Ltd
- Insiders 71.30%
- Institutions 7.14%
- Public & others 21.56%
- Shares outstanding 571M
- Free float 162M
Autobio Diagnostics Co Ltd company profile
- Company name
- Autobio Diagnostics Co Ltd
- Ticker
- 603658.SHG
- ISIN
- CNE100002GC4
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 5,700
- Fiscal year end
- December
- Address
- No. 199, Jingkai 15th Street, Zhengzhou, China, 450016
- Phone
- 86 40 0056 9995
- Website
- autobio.com.cn
About Autobio Diagnostics Co Ltd
Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. The company offers immunoassay, biochemistry, and microbiology products; reagents and instruments; and technical and support, and training services, as well as engages in biology research and development activities. Its immunoassay products consist of AutoLumo S900 and AutoLumo A1860 that provides user experience for small and medium size labs; AutoLumo A6200/A6600, an automatic immunoassay analyzer; AutoLumo A2000 Plus, an automated chemiluminescence immunoassay analyzer; PHOmo microplate readers; LUmo microplate luminometers; and iWO-960 microplate washers. The company's microbiology products include AutoMic-I60 for microbial identification and antibiotic susceptibility testing; AutoStreak S1800, a microbial sample pretreatment system; Autof T series and MALDI-TOF MS system for the identification of pathogenic bacteria; AutoMimo 1200, an instrument for improving pipetting efficiency and optimize workflow in the lab; BC60, an automatic blood culture instrument; and BC120, an automated bacterial culturing and detection. It also provides blood culture bottles and mycoplasma TIES reagents; AutoMolec 1600, an integrated and automated molecular diagnostics analyzer; AutoMolec 3000, an in vitro molecular detection instrument; Ci-120x and Ci-310 benchtop coagulation analyzers; and Autolas Bi 1000, Autolas Bi2600, AutoChem B861, and AutoChem B2000 automated biochemistry analyzers, as well as Autolas X series, and Autolas B series. The company was formerly known as Lifeclone Diagnostics Co., Ltd. and changed its name to Autobio Diagnostics Co., Ltd. in 2003. Autobio Diagnostics Co., Ltd. was founded in 1998 and is headquartered in Zhengzhou, China. Autobio Diagnostics Co., Ltd. is a subsidiary of Zhengzhou Autobio Co., Ltd.
Autobio Diagnostics Co Ltd management
8- Mr. Zeng Li YangGM & Director · born 1968
- Ms. Wei LiuEmployee Representative Director & Director of Administrative Center · born 1976
- Mr. Rui Kuan FangDeputy GM & Secretary of the Board of Directors · born 1971
- Mr. Xue Wei WuDeputy GM & Director · born 1967
- Mr. Guang Yu FuExecutive Deputy GM & Director · born 1969
- Ms. Chao Jie FengDirector · born 1978
- Mr. Rui Feng ZhangExecutive Deputy GM & Director · born 1975
- Dongdong WangChief Financial Officer